迟发性运动障碍的危险因素评估。

Q3 Medicine
Psychopharmacology bulletin Pub Date : 2020-07-23
Melek Kanarya Vardar, Mehmet Emin Ceylan, Bariş Önen Ünsalver
{"title":"迟发性运动障碍的危险因素评估。","authors":"Melek Kanarya Vardar,&nbsp;Mehmet Emin Ceylan,&nbsp;Bariş Önen Ünsalver","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Aim of the study is to evaluate sociodemographic and clinical features that may be associated with the development of Tardive dyskinesia (TD).</p><p><strong>Methods: </strong>80 patients attending an outpatient psychiatry clinic in Istanbul, Turkey were divided into TD (n = 50) and control groups (CG) (n = 30). Sociodemographic and clinical data was collected through face-to-face interviews and a retrospective search of medical records.</p><p><strong>Results: </strong>There was a significant difference between TD and control group (CG) in terms of mean; onset of psychiatric disease at or after 35 years of age; first use of APD at or after 35 years of age; use of long-acting injectable APD; history of extrapyramidal side-effects; history of akathisia and family history of psychiatric disease. There was no significant difference between the two groups in terms of DSM- IV-based psychiatric diagnosis distributions, the existence of complete recovery periods during the course of the disease; total duration of APD use for at least 10 years; APD holidays; regular APD use; history of ECT and smoking or alcohol and substance abuse/addiction.</p><p><strong>Conclusion: </strong>Advancing age seemed to be the most significant risk factor in the development of TD. Clinicians need to be cautious about TD when prescribing APD for elderly patients.</p>","PeriodicalId":21069,"journal":{"name":"Psychopharmacology bulletin","volume":"50 3","pages":"36-46"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377543/pdf/PB-50-3-36.pdf","citationCount":"0","resultStr":"{\"title\":\"Assesment of Risk Factors for Tardive Dyskinesia.\",\"authors\":\"Melek Kanarya Vardar,&nbsp;Mehmet Emin Ceylan,&nbsp;Bariş Önen Ünsalver\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Aim of the study is to evaluate sociodemographic and clinical features that may be associated with the development of Tardive dyskinesia (TD).</p><p><strong>Methods: </strong>80 patients attending an outpatient psychiatry clinic in Istanbul, Turkey were divided into TD (n = 50) and control groups (CG) (n = 30). Sociodemographic and clinical data was collected through face-to-face interviews and a retrospective search of medical records.</p><p><strong>Results: </strong>There was a significant difference between TD and control group (CG) in terms of mean; onset of psychiatric disease at or after 35 years of age; first use of APD at or after 35 years of age; use of long-acting injectable APD; history of extrapyramidal side-effects; history of akathisia and family history of psychiatric disease. There was no significant difference between the two groups in terms of DSM- IV-based psychiatric diagnosis distributions, the existence of complete recovery periods during the course of the disease; total duration of APD use for at least 10 years; APD holidays; regular APD use; history of ECT and smoking or alcohol and substance abuse/addiction.</p><p><strong>Conclusion: </strong>Advancing age seemed to be the most significant risk factor in the development of TD. Clinicians need to be cautious about TD when prescribing APD for elderly patients.</p>\",\"PeriodicalId\":21069,\"journal\":{\"name\":\"Psychopharmacology bulletin\",\"volume\":\"50 3\",\"pages\":\"36-46\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377543/pdf/PB-50-3-36.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology bulletin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究的目的是评估可能与迟发性运动障碍(TD)发展相关的社会人口学和临床特征。方法:80例在土耳其伊斯坦布尔精神病门诊就诊的患者分为TD组(n = 50)和对照组(n = 30)。通过面对面访谈和对医疗记录的回顾性检索收集了社会人口学和临床数据。结果:TD组与对照组(CG组)的平均值有显著性差异;35岁或35岁以后出现精神疾病;35岁或以后首次使用APD;长效注射APD的使用;锥体外系副作用史;无静坐症病史及精神疾病家族史。两组在基于DSM- iv的精神病学诊断分布、病程中存在完全恢复期方面无显著差异;APD的总使用时间至少为10年;美国假期;定期使用APD;有电痉挛史、吸烟或酗酒史以及药物滥用/成瘾史。结论:高龄似乎是TD发生的最重要危险因素。临床医生在为老年患者开APD处方时需要谨慎对待TD。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Assesment of Risk Factors for Tardive Dyskinesia.

Objective: Aim of the study is to evaluate sociodemographic and clinical features that may be associated with the development of Tardive dyskinesia (TD).

Methods: 80 patients attending an outpatient psychiatry clinic in Istanbul, Turkey were divided into TD (n = 50) and control groups (CG) (n = 30). Sociodemographic and clinical data was collected through face-to-face interviews and a retrospective search of medical records.

Results: There was a significant difference between TD and control group (CG) in terms of mean; onset of psychiatric disease at or after 35 years of age; first use of APD at or after 35 years of age; use of long-acting injectable APD; history of extrapyramidal side-effects; history of akathisia and family history of psychiatric disease. There was no significant difference between the two groups in terms of DSM- IV-based psychiatric diagnosis distributions, the existence of complete recovery periods during the course of the disease; total duration of APD use for at least 10 years; APD holidays; regular APD use; history of ECT and smoking or alcohol and substance abuse/addiction.

Conclusion: Advancing age seemed to be the most significant risk factor in the development of TD. Clinicians need to be cautious about TD when prescribing APD for elderly patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Psychopharmacology bulletin
Psychopharmacology bulletin PHARMACOLOGY & PHARMACY-PSYCHIATRY
CiteScore
2.70
自引率
0.00%
发文量
32
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信